3 ms·
As someone who works in the industry, you are somewhat correct. Once a drug is approved, it is priced independently of the R&D cost. However, the decision to
by refurb 8y ago
As someone who works in the industry, you are somewhat correct. Once a drug is approved, it is priced independently of the R&D cost.
However, the decision to bring a drug through clinical trials (the "D" in "R&D") is gated. The potential price of the drug is estimated and the financial costs and potential return are calculated. If the return isn't that great because you can't get the volume or price, the R&D investment isn't made and the drug "dies".
So in other words, price controls on drugs would lower the prices of drugs already approved, but it would likely also kill a number of drugs currently in development.
- tobylane 8y agoThere's sticker price and there's what buyers with the ability to negotiate pays. I hear the government healthcare suppliers (Medicare, Medicaid and VA) aren't allowed to ask for lower prices for bulk despite being some of the world's largest customers, each.
- kingaillas 8y ago>I hear the government healthcare suppliers (Medicare, Medicaid and VA) aren't allowed to ask for lower prices for bulk despite being some of the world's largest customers, each. Yep, that's part of Medicare Part D, in turn part of the "Medicare Prescription Drug, Improvement, and Modernization Act", and went into effect in 2003 under Bush 43.
- refurb 8y agoThat's not true in the slightest. Medicare - gets an automatic discount equal to the average discount that commercial customers pay Medicaid - gets another 23.1% discount on top of what Medicare gets VA - lowest price of all customers, get at least a 24% discounts on top of what Medicare gets